LOS ANGELES, Oct. 30, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI) today announced that it will report third quarter 2024 financial results and provide recent corporate updates on Wednesday, November 6, 2024. These results will be available under the "Investors & News" page of the Aadi Bioscience website at aadibio.com.
About Aadi Bioscience
Aadi is a precision oncology company focused on the commercialization of FYARRO® for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa). More information on the Company is available on the Aadi website at www.aadibio.com and connect with us on Twitter and LinkedIn.
Contact:
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$3.00 |
| Daily Volume: | 0 |
| Market Cap: | US$74.040M |
December 19, 2024 November 06, 2024 August 20, 2024 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
